Dr. Antonio Giordano

Oncology | Hematology Oncology
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonio Giordano is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Giordano is rated as an Experienced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Breast Cancer, and Paget Disease of the Breast. Dr. Giordano is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in SC
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Phase III Placebo-Controlled Trial to Evaluate Dexamethasone Use for Everolimus-Induced Oral Stomatitis: Prevention Versus Early Treatment Approaches: MIST (My Individualized Stomatitis Treatment)
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Enrollment Status: Terminated
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: OPC
Study Phase: Phase 1
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Procedure
View 6 Less Clinical Trials
Similar Doctors
James A. Decaprio
Advanced in Retinoblastoma
Dr. James A. Decaprio
Oncology
Advanced in Retinoblastoma
Dr. James A. Decaprio
Oncology
44 Binney St, M457, 
Boston, MA 
 (0.1 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances

James Decaprio is an Oncologist in Boston, Massachusetts. Dr. Decaprio is rated as a Distinguished provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Merkel Cell Carcinoma, Neuroendocrine Tumor, Retinoblastoma, Squamous Cell Skin Carcinoma, and Bone Marrow Aspiration.

Advanced in Retinoblastoma
Dr. Shom Goel
Oncology
Advanced in Retinoblastoma
Dr. Shom Goel
Oncology
450 Brookline Ave, Yawkey 12, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-335-3937
Languages Spoken:
English

Shom Goel is an Oncologist in Boston, Massachusetts. Dr. Goel is rated as an Advanced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Breast Cancer, Retinoblastoma, Agranulocytosis, and Triple-Negative Breast Cancer.

Advanced in Retinoblastoma
Dr. Myles A. Brown
Oncology
Advanced in Retinoblastoma
Dr. Myles A. Brown
Oncology
44 Binney St, 
Boston, MA 
 (0.1 miles away)
617-632-3948
Languages Spoken:
English

Myles Brown is an Oncologist in Boston, Massachusetts. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Breast Cancer, Prostate Cancer, Multiple Endocrine Neoplasia Type 1, Retinoblastoma, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Giordano's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile